Scott R. Solomon, MD, discusses the rationale for examining lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
Scott R. Solomon, MD, medical director of the Blood and Marrow Transplant Matched Unrelated Donor Program and the Stem Cell Processing Laboratory, and a physician in the Leukemia Program, at Northside Hospital, discusses the rationale for examining lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell lymphoma (LBCL).
It is well known that CD19-targeted CAR T-cell therapies have demonstrated significant efficacy in patients with relapsed/refractory LBCL. As such, this modality has become the standard of care in the third-line setting, according to Solomon. One important question that still needs to be addressed is whether liso-cel will continue to maintain efficacy in patients who have had prior exposure to anti-CD19 therapies, including monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates, Solomon says.
CD19-targeted regimens are now commonly used in clinical research that is being done in patients with LBCL, and many patients who have been exposed to anti-CD19 agents are going on to receive CAR T-cell therapy, Solomon concludes.